Literature DB >> 22258501

Using HIV viral load to guide treatment-for-prevention interventions.

Vladimir Novitsky1, Max Essex.   

Abstract

PURPOSE OF REVIEW: To provide evidence that HIV-1 RNA load can guide treatment-for-prevention interventions to mitigate the HIV epidemic. RECENT
FINDINGS: Some HIV-infected individuals maintain increased levels of HIV-1 RNA load after acute infection for an extended period of time, and can disproportionately contribute to the spread of HIV in the community. The recent HIV Prevention Trials Network 052 study has demonstrated 96% efficacy for initiation of early antiretroviral treatment (ART) in HIV-1 serodiscordant couples.
SUMMARY: The level of HIV-1 RNA load in plasma is the major biological predictor of virus transmission. HIV-infected individuals who maintain increased levels of HIV-1 RNA load, extended high viremics, can transmit virus at higher rates. Combinatorial ART decreases HIV replication, thus reducing rates of virus transmission. Identifying high viremics and placing them on ART seems an attractive strategy that has the potential to achieve both individual benefits by lowering risk for early onset of clinical AIDS and public health benefits by reducing HIV transmission. A key logistical challenge is to screen for high viremics among HIV-positive individuals. Efficacy of the modified treatment-for-prevention approach focused on high viremics is being evaluated in ongoing and upcoming clinical trials. If efficacious, such an approach could be used widely to mitigate and control the HIV epidemic.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22258501     DOI: 10.1097/COH.0b013e32834fe8ff

Source DB:  PubMed          Journal:  Curr Opin HIV AIDS        ISSN: 1746-630X            Impact factor:   4.283


  18 in total

1.  Depression, substance use, viral load, and CD4+ count among patients who continued or left antiretroviral therapy for HIV in St. Petersburg, Russian Federation.

Authors:  Anna Pecoraro; Matthew Mimiaga; Conall O'Cleirigh; Steven A Safren; Elena Blokhina; Elena Verbitskaya; Tatiana Yaroslavtseva; Andrey Ustinov; Dmitry A Lioznov; Edwin Zvartau; Evgeny Krupitsky; George E Woody
Journal:  AIDS Care       Date:  2014-09-29

2.  The Anticipated Clinical and Economic Effects of 90-90-90 in South Africa.

Authors:  Rochelle P Walensky; Ethan D Borre; Linda-Gail Bekker; Stephen C Resch; Emily P Hyle; Robin Wood; Milton C Weinstein; Andrea L Ciaranello; Kenneth A Freedberg; A David Paltiel
Journal:  Ann Intern Med       Date:  2016-05-31       Impact factor: 25.391

3.  Finding those at risk: acute HIV infection in Newark, NJ.

Authors:  Eugene G Martin; Gratian Salaru; Debbie Mohammed; Robert W Coombs; Sindy M Paul; Evan M Cadoff
Journal:  J Clin Virol       Date:  2013-08-13       Impact factor: 3.168

Review 4.  Phylogenetic inferences on HIV-1 transmission: implications for the design of prevention and treatment interventions.

Authors:  Bluma Brenner; Mark A Wainberg; Michel Roger
Journal:  AIDS       Date:  2013-04-24       Impact factor: 4.177

5.  High HIV-1 RNA Among Newly Diagnosed People in Botswana.

Authors:  Vladimir Novitsky; Melanie Prague; Sikhulile Moyo; Tendani Gaolathe; Mompati Mmalane; Etienne Kadima Yankinda; Unoda Chakalisa; Refeletswe Lebelonyane; Nealia Khan; Kathleen M Powis; Erik Widenfelt; Simani Gaseitsiwe; Scott L Dryden-Peterson; Molly Pretorius Holme; Victor De Gruttola; Pam Bachanas; Joseph Makhema; Shahin Lockman; M Essex
Journal:  AIDS Res Hum Retroviruses       Date:  2018-01-17       Impact factor: 2.205

Review 6.  Diagnosis of Human Immunodeficiency Virus Infection.

Authors:  Bharat S Parekh; Chin-Yih Ou; Peter N Fonjungo; Mireille B Kalou; Erin Rottinghaus; Adrian Puren; Heather Alexander; Mackenzie Hurlston Cox; John N Nkengasong
Journal:  Clin Microbiol Rev       Date:  2018-11-28       Impact factor: 26.132

7.  Sample size considerations in the design of cluster randomized trials of combination HIV prevention.

Authors:  Rui Wang; Ravi Goyal; Quanhong Lei; M Essex; Victor De Gruttola
Journal:  Clin Trials       Date:  2014-06       Impact factor: 2.486

8.  Preclinical pharmacokinetics and tissue distribution of long-acting nanoformulated antiretroviral therapy.

Authors:  Nagsen Gautam; Upal Roy; Shantanu Balkundi; Pavan Puligujja; Dongwei Guo; Nathan Smith; Xin-Ming Liu; Benjamin Lamberty; Brenda Morsey; Howard S Fox; Joellyn McMillan; Howard E Gendelman; Yazen Alnouti
Journal:  Antimicrob Agents Chemother       Date:  2013-04-22       Impact factor: 5.191

9.  Methadone maintenance therapy decreases the rate of antiretroviral therapy discontinuation among HIV-positive illicit drug users.

Authors:  H Reddon; M-J Milloy; A Simo; J Montaner; E Wood; T Kerr
Journal:  AIDS Behav       Date:  2014-04

10.  Psychiatric Distress, Drug Use, and HIV Viral Load Suppression in Russia.

Authors:  A Ustinov; A Suvorova; A Belyakov; A Makhamatova; O Levina; E Krupitsky; D Lioznov; L Niccolai; R Heimer
Journal:  AIDS Behav       Date:  2016-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.